AZD5363 (Capivasertib) Mechanism of Action: AKT Inhibition in Breast Cancer Cells Research

AZD5363 (Capivasertib) MOA:Targeting AKT/PI3K-AKT-PTEN for Breast Cancer

🎯 check AZD5363 (Capivasertib) product page

AZD5363 (Capivasertib) is a potent, ATP-competitive pan-AKT inhibitor. It affects PI3K/AKT/mTOR signaling by binding to the AKT kinase domain and suppressing downstream effectors, effectively inhibiting tumor cell proliferation and promoting apoptosis.

Primary Applications and Mechanism of Action